Bioanalytical Solutions

What we do

Analytical services

We offer you

Protein Biomarkers

Protein biomarkers are optimal for early phenotypic diagnosis or monitoring treatment response. Protein markers offer a significantly higher degree of differentiated information compared to genomic markers and will immediately mirror the state of the biological system. In addition, proteins provide the direct functionality which makes them essential in understanding disease pathology and other biological phenomena.

The majority of protein biomarkers are low abundant proteins found in minimally-invasive samples such as blood serum, urine, saliva and other accessible body fluids. However, understanding disease pathology often requires more insight, therefore we offer biomarker studies on a wealth of sample types, for example tissue biopsies, plasma, cerebrospinal fluids, microvesicles, cell lysates etc. Most of our assays are developed to human samples but can be used with success for a variety of other species.

Using Proximity Extension Assay (Olink Proteomics) we can provide disease-focused screening of 92 protein biomarkers measured simultaneously using only 1µL sample. Each panel of 92 biomarkers are targeted at a specific disease or key biological process. The panels cover a total of 1165 clinically relevant proteins, divided into 15 different focused biomarker panels, e.g. oncology, immuno-oncology, inflammation, immune response, cardiovascular disease, neurology, cell regulation and development, metabolism, organ damage and a translational mouse panel. 

Using nCounter® (nanoString Technologies) we offer digital single molecule detection. The analyses have a high multiplex level with approximately 30 biomarkers in each panel. The panels are focused to immune cell profiling, cell signalling, solid tumor lysate with focus on phosphorylated proteins and a hematology panel for lysate and FFPE samples. The technology is fully automated to ensure precise and reproducible measurements, across many sample types, including low-quality samples and FFPE tissue.

The nCounter® system also permits simultaneous quantification of DNA, RNA and protein, allowing you to compare genotype with gene and protein expression.

Technologies for protein biomarker screening:

Proximity Extension Assay (Olink Proteomics)

nCounter® SPRINT (NanoString Technologies)

Electrochmiluminiscence MultiArray Technology (Meso Scale Discovery®)

miRNA BIOMARKERS

MicroRNAs (miRNAs) are a group of small non-coding RNAs that are involved in regulating a range of developmental and physiological processes; their dysregulation has been associated with development of diseases. Circulating miRNAs and exosomal miRNAs have also been proposed as being useful in diagnostics as biomarkers for diseases and for monitoring treatment.

BioXpedia offers miRNA biomarker screening for the investigation of regulatory functions related to cell growth, development, differentiation and a variety of human diseases. Depending on the application and the purpose of the analysis BioXpedia offers different miRNA profiling techniques.

Using the Fluidigm Biomark HD system we provide miRNA expression profiling and experimental validation in a variety of sample types. The Biomark system ensures efficient, high-throughput processing of miRNA samples with increased speed and reproducibility. The technology is fast and only requires small sample volumes in the nanoliter scale, making it ideal for miRNA profiling.

With the nCounter® miRNA Expression Assays from NanoString Technologies we perform highly multiplexed, direct digital detection and quantification of miRNAs in a single reaction. The assays are optimized for robust performance across a variety of sample types and in a wide range of biological areas of research, including cell signalling, neuroscience, stem cell research, autophagy, infectious disease, and immunology. The nCounter® technology allows simultaneous measurement of miRNA and mRNA from the same sample, making it ideal to study the impact of miRNAs on their target mRNAs.

Technologies for miRNA biomarker screening:

Fluidigm Biomark HD miRNA profiling (Fluidigm)

nCounter® SPRINT (nanoString Technologies)

SNP Genotyping

SNPs (single nucleotide polymorphisms) or point mutations are the most common types of genetic variation determining a major part of the phenotypic diversity between individuals. Causal point mutations change the amino acid sequence of the encoded protein and hence such SNPs can be used as markers for development of companion diagnostics and stratification of patients.

BioXpedia offers SNP genotyping for investigation of genetic associations, structural changes, copy number variations or loss of heterozygosity (LOH). Additionally, we provide SNP tracing for standardized authentication and quality control check of biobank samples and cell lines. We offer different genotyping technologies depending on the application and the purpose of the analysis, the number of SNPs per sample and the number of samples in the study.

 

We provide gene-wide SNP genotyping, e.g. fine mapping or haplotyping of candidate regions including the analysis of <500 SNPs using the Fluidigm Biomark HD. The Fluidigm System enables efficient, high-throughput processing of SNP genotyping samples with increased speed and reproducibility, and with small quantities of DNA required, which makes it ideal for precious sample analysis.

Especially suited to FFPE samples is the nCounter® DNA Assays to investigate mutational status. These assays are highly optimized for robust performance on FFPE samples and provides simple multiplexing of genetic and copy number variation (CNV) while providing precise, accurate, and robust results. With the shortest hands-on time of any DNA analysis platform, the nCounter® Analysis System is ideal for translation and routine screening applications.

Technologies for SNP genotyping:

Fluidigm Biomark HD profiling (Fluidigm)

nCounter® SPRINT (NanoString Technologies)

Gene expression biomarkers

Analysis of changes in gene expression levels is the first level of exploration for any regulation at the molecular and cellular levels. Transcription of genes is a very dynamic process, allowing cells to adapt rapidly to external, environmental or physiological changes. Therefore, gene expression profiling is a very powerful way of identifying biomarkers that describe a given physiological state, disease or exposure to drugs.

BioXpedia provides gene expression biomarker screening using technologies that are time-, cost-, and sample-effective, allowing profiling of the RNA content at single cell level.

 

With the Fluidigm BioMark HD technology rapid and reproducible result are ensured with an automated workflow on Integrated Fluidic Circuits (chips) with reaction chambers of less than 10nl. The high capacity, multiplex level system enables simultaneous detection of 96 assays in 96 samples creating 9.216 data points in a single run. Therefore, the technology offers production scale throughput and exquisite single cell sensitivity with a wide range of genomic applications, making it flexible to your own design.

Using the nCounter Gene Expression Panels from nanoString Technologies, we perform highly multiplexed, direct digital detection and quantification of mRNA molecules in a single reaction. The assays are optimized for robust performance across a variety of sample types and in a wide range of biological areas of research. The nanoString technology can detect target molecules as small as 100 base pairs with less than 100ng of input material. This enables multiplex gene expression profiling with single cell worth of input.

Technologies for screening of RNA biomarkers:

Fluidigm Biomark HD miRNA profiling (Fluidigm)

nCounter SPRINT (nanoString Technologies)

Extraction and isolation of biomarkers

BioXpedia offers sample preparation and high-quality extraction of the molecules of interest – DNA, RNA species and proteins – for any downstream analysis.

We provide extraction from plasma, serum, whole blood, tissue biopsies and FFPE tissue along with any other biofluid sample such as urine, cerebrospinal fluid, saliva, and tear fluid. Furthermore, cultured cells and medium from cell cultures can be used as a source for extraction of the biomarker molecules of interest.

Our extraction methods are suitable for mRNA extraction and small RNA species such as miRNA. Additionally, we offer isolation of RNA from extravesicular vesicles like exosomes derived from plasma, serum and other biofluid samples.

 

 

Extraction of protein biomarkers is optimized for the specific sample type, e.g. cells or tissue, to ensure extraction of native proteins and avoid degradation of proteins prior to analysis. The concentration and quality of extracted DNA and RNA is assessed by state-of-the-art technologies (4200 TapeStation, QIAxpert) to assure high quality input material for our downstream analyses.

Automated workflow and robotic pipetting is used whenever possible to ensure maximum reproducibility and efficacy.

If your research is specifically focused on a sample type not mentioned above, please do not hesitate to contact us for a discussion.

Pilot project

Open protein biomarker PEA panels

Each protein biomarker panel (PEA) provide disease-focused screening of 92 protein biomarkers. The PEA technology is run using Fluidigm 96.96 IFC chip, thus each run (chip) has space for 90 patient samples plus assay controls.

However, if you have a small project or need to run a pilot project before initiating a large-scale study including many clinical samples, it is possible to team up with other researchers to share costs.

Pilot projects running on shared chips will await a sufficient number of samples for the panel, thus a longer delivery time can be expected. We will of course keep you updated on the timeline for your project.

More information on the Proximity Extension Assay here

research projects

Joint R&D projects – Scientific excellence together

BioXpedia is eager to participate in national and international biomarker research and development projects. We may contribute to innovative research as service provider or as SME-partner in grant proposals or research consortia. BioXpedia is ready to establish true research collaboration by exchanging knowledge, data and research expertise for shared research projects, developing scientific and commercial innovations.

BioXpedia participates actively in international funding programs such as H2020 and Eureka-Eurostars and Danish research programs run by Innovation Fund Denmark, the Lundbeck Foundation and the Novo Nordisk Foundation.

A background with many years of scientific research and experience from several successful R&D projects, makes BioXpedia the ideal partner for establishing partnerships for biomarker discovery and validation.

If you are interested in exploring collaboration opportunities, please contact us

Custom

Services

BioXpedia offers a customized full service to ensure that you get the most out of your valuable samples. From the beginning of your project, we provide expert consulting and support to help you determining the optimal experimental setup to identify new clinically useful biomarkers and drug targets for treatment.

We offer you a fast track to precision medicine by handling the practicalities, from sample preparation and amplification to helping with the final data analysis.

As an additional service BioXpedia offers to manage the contact with other biochemical and analytical laboratories providing services not implemented at BioXpedia. To ensure you a minimum workload we will handle the sample preparation and shipping of your samples.

Quality Assurance

BioXpedia is in all aspects committed to operate under controlled conditions and under the highest level of quality.

N

All laboratory work is performed according to Standard Operational Procedures (SOPs)

N

Highly skilled personnel trained for the procedures.

N

All analytical methods are experimentally validated

N

Only high-quality reagents and kits with valid Certificate of Analysis (CoA) are used

N

All instruments and lab equipment are qualified and calibrated

N

All SOPs are under continuous evaluation for quality improvement